Inquiry Basket
Loading ......
Atezolizumab is a humanized immunoglobulin gamma one (IgG1) monoclonal antibody that targets programmed death-ligand one (PD-L1), a critical immune checkpoint protein expressed on the surface of tumor cells and tumor-infiltrating immune cells. By binding to PD-L1, Atezolizumab blocks the interaction between PD-L1 and its receptors programmed death-one (PD-1) and CD80, thereby reactivating the anti-tumor immune response that is often suppressed in the tumor microenvironment. This mechanism of action has established Atezolizumab as an important therapeutic option for multiple cancer indications including urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma.In addition to immunogenicity testing, quantification of free Atezolizumab concentrations in biological matrices is critical for pharmacokinetic characterization and therapeutic drug monitoring. Understanding the relationship between drug exposure and clinical response enables dose optimization and supports regulatory submissions.
Figure 1.Anti-Atezolizumab Antibody Detection.
The programmed death pathway is a critical regulator of immune responses that maintains self-tolerance and limits tissue damage during inflammation. Under normal physiological conditions, engagement of PD-1 on activated T cells by its ligands PD-L1 or PD-L2 delivers an inhibitory signal that dampens T cell activity. Many cancers exploit this pathway by upregulating PD-L1 expression on tumor cells or on immune cells within the tumor microenvironment, creating a shield that protects the tumor from immune-mediated destruction. PD-L1 is a transmembrane protein expressed on a wide variety of cell types including tumor cells, antigen-presenting cells, and other immune cells. The interaction between PD-L1 and PD-1 on T cells triggers downstream signaling events that inhibit T cell proliferation, cytokine production, and cytotoxic activity. By co-opting this endogenous inhibitory mechanism, tumors evade immune surveillance and establish an immunosuppressive environment that supports tumor growth and metastasis.
Atezolizumab binds with high affinity and specificity to PD-L1, blocking its interaction with both PD-1 and CD80. By occupying the PD-L1 binding interface, Atezolizumab prevents engagement of PD-1 on T cells, thereby removing the inhibitory signal that would otherwise suppress T cell activity. This blockade restores T cell function, enabling anti-tumor immune responses that can eliminate cancer cells. The unique binding properties of Atezolizumab distinguish it from other PD-1 or PD-L1 targeting antibodies. Atezolizumab does not interfere with the interaction between PD-L2 and PD-1, preserving some aspects of immune regulation while blocking the dominant inhibitory pathway. Additionally, Atezolizumab lacks antibody-dependent cellular cytotoxicity activity due to modifications in its Fc region, preventing depletion of PD-L1-expressing immune cells that could compromise the anti-tumor response.
Therapeutic drug monitoring involves measuring drug concentrations in individual patients to guide dosing decisions. For immune checkpoint inhibitors like Atezolizumab, the relationship between drug exposure and clinical response is an active area of investigation. Some studies have suggested that higher drug concentrations may be associated with improved outcomes, though exposure-response relationships vary across indications and patient populations. The Free Atezolizumab ELISA Kit enables accurate measurement of unbound Atezolizumab concentrations in biological matrices, providing critical data for pharmacokinetic assessments and therapeutic drug monitoring studies. Quantification of free drug levels can help clinicians assess whether therapeutic concentrations are achieved and maintained throughout the dosing interval.
The Anti-Atezolizumab ELISA Kit is designed for the detection and semi-quantitative determination of anti-Atezolizumab antibodies in human serum, plasma, or other biological fluids. This kit is optimized for immunogenicity assessment in clinical research and regulatory-compliant environments.
The Free Atezolizumab ELISA Kit is specifically designed for the quantification of free Atezolizumab concentrations in human serum, plasma, or other biological matrices. This kit is optimized for pharmacokinetic studies and therapeutic drug monitoring applications.
Atezolizumab is a cornerstone of cancer immunotherapy, reactivating anti-tumor immune responses by blocking the PD-L1 immune checkpoint. Immunogenicity assessment and pharmacokinetic monitoring are essential components of the clinical development and post-marketing surveillance of this important therapeutic antibody. The Anti-Atezolizumab ELISA Kit provides a validated, sensitive, and specific solution for detecting anti-Atezolizumab antibodies, supporting immunogenicity testing that meets regulatory expectations. The Free Atezolizumab ELISA Kit enables accurate quantification of unbound drug concentrations, facilitating pharmacokinetic characterization and therapeutic drug monitoring. Together, these kits provide a comprehensive toolkit for the bioanalytical characterization of Atezolizumab across all stages of development and clinical use. As immune checkpoint inhibitors continue to transform cancer treatment, reliable ELISA-based methods will remain essential for optimizing the use of these therapies in clinical practice.
| Cat. No. | Product Name | Species Reactivity | Detection Method | |
| DEIA-JY25011 | Free Atezolizumab ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25031 | Total Atezolizumab ELISA Kit | Human | ELISA | Inquiry |
| DEIA-JY25049 | Anti-Atezolizumab ELISA Kit | Human | ELISA | Inquiry |
Loading ......
